Anti-tuberculous combination therapy
This page covers all Anti-tuberculous combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mycobacterial ATP synthase (bedaquiline), mycobacterial DNA/proteins (pretomanid), bacterial ribosome (linezolid).
Targets
Marketed (4)
- Treatment regimens for MDR-TB · Shanghai Pulmonary Hospital, Shanghai, China · Infectious Disease
MDR-TB treatment regimens combine multiple anti-tuberculous drugs to overcome drug resistance and eliminate Mycobacterium tuberculosis. - New regimen(BdqCfzLzd+XY) · Shanghai Pulmonary Hospital, Shanghai, China · Infectious Disease
This is a combination regimen of bedaquiline, clofazimine, linezolid, and two additional agents (XY) designed to treat drug-resistant tuberculosis by targeting multiple mycobacterial pathways simultaneously. - BDL regimen · Beijing Chest Hospital · Infectious Disease
BDL is a combination chemotherapy regimen used to treat tuberculosis by combining multiple anti-tuberculous agents. - MDR-TB Treatment Regimen(WHO) · Shanghai Pulmonary Hospital, Shanghai, China · Infectious Disease
A standardized combination regimen of multiple anti-tuberculous drugs designed to overcome drug resistance in multidrug-resistant tuberculosis (MDR-TB) by targeting Mycobacterium tuberculosis through multiple mechanisms simultaneously.
Phase 3 pipeline (1)
- BPaL · Otsuka Pharmaceutical Development & Commercialization, Inc. · Infectious Disease
BPaL is a three-drug combination regimen (bedaquiline, pretomanid, and linezolid) that inhibits mycobacterial ATP synthase and protein synthesis to kill drug-resistant tuberculosis bacteria.
Patent intelligence
- tuberculous combination therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates